Disease Landscape and Forecast Insights

In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $120 billion in the major pharmaceutical markets under study (United…

In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…

Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Two high-priced JAK inhibitors (Incyte’s Jakafi and BMS’s Inrebic)…

Treatment of small-cell lung cancer (SCLC) has long been dominated by chemo(radio)therapy, but the standard of care for first-line extensive-stage SCLC recently changed, following the FDA’s…

Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin…

Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…

Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…

Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…

Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal (IVT) pharmacotherapy approvals across different drug…